Literature DB >> 17486075

A genetic mouse model for metastatic lung cancer with gender differences in survival.

S Zheng1, A K El-Naggar, E S Kim, J M Kurie, G Lozano.   

Abstract

Lung cancer is a devastating disease with poor prognosis. The design of better therapies for lung cancer patients would be greatly aided by good mouse models that closely resemble the human disease. Unfortunately, current models for lung adenocarcinoma are inadequate due to the absence of metastases. In this study, we incorporated both K-ras and p53 missense mutations into the mouse genome and established a more faithful genetic model for human lung adenocarcinoma, the most common type of lung cancer. Mice with both mutations developed advanced lung adenocarcinomas that were highly aggressive and metastasized to multiple intrathoracic and extrathoracic sites in a pattern similar to that of human lung cancer. These mice also showed a gender difference in cancer-related death. Additionally, the presence of both mutations induced pleural mesotheliomas in 23% of these mice. This mouse model recapitulates the metastatic nature of human lung cancer and will be invaluable to further probe the molecular basis of metastatic lung cancer and for translational studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486075     DOI: 10.1038/sj.onc.1210493

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

Review 1.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

2.  Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

Authors:  Alexander E Kudinov; Alexander Deneka; Anna S Nikonova; Tim N Beck; Young-Ho Ahn; Xin Liu; Cathleen F Martinez; Fred A Schultz; Samuel Reynolds; Dong-Hua Yang; Kathy Q Cai; Khaled M Yaghmour; Karmel A Baker; Brian L Egleston; Emmanuelle Nicolas; Adaeze Chikwem; Gregory Andrianov; Shelly Singh; Hossein Borghaei; Ilya G Serebriiskii; Don L Gibbons; Jonathan M Kurie; Erica A Golemis; Yanis Boumber
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

3.  ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.

Authors:  Yanan Yang; Young-Ho Ahn; Yulong Chen; Xiaochao Tan; Lixia Guo; Don L Gibbons; Christin Ungewiss; David H Peng; Xin Liu; Steven H Lin; Nishan Thilaganathan; Ignacio I Wistuba; Jaime Rodriguez-Canales; Georgia McLendon; Chad J Creighton; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

4.  Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.

Authors:  Mark J Schliekelman; Don L Gibbons; Vitor M Faca; Chad J Creighton; Zain H Rizvi; Qing Zhang; Chee-Hong Wong; Hong Wang; Christin Ungewiss; Young-Ho Ahn; Dong-Hoon Shin; Jonathan M Kurie; Samir M Hanash
Journal:  Cancer Res       Date:  2011-10-10       Impact factor: 12.701

5.  Multiple stress signals activate mutant p53 in vivo.

Authors:  Young-Ah Suh; Sean M Post; Ana C Elizondo-Fraire; Daniela R Maccio; James G Jackson; Adel K El-Naggar; Carolyn Van Pelt; Tamara Terzian; Guillermina Lozano
Journal:  Cancer Res       Date:  2011-10-07       Impact factor: 12.701

6.  Obligate progression precedes lung adenocarcinoma dissemination.

Authors:  Deborah R Caswell; Chen-Hua Chuang; Dian Yang; Shin-Heng Chiou; Shashank Cheemalavagu; Caroline Kim-Kiselak; Andrew Connolly; Monte M Winslow
Journal:  Cancer Discov       Date:  2014-04-16       Impact factor: 39.397

7.  TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.

Authors:  Nagako Akeno; Alisa L Reece; Melissa Callahan; Ashley L Miller; Rebecca G Kim; Diana He; Adam Lane; Jonathan S Moulton; Kathryn A Wikenheiser-Brokamp
Journal:  Mol Cancer Ther       Date:  2017-08-28       Impact factor: 6.261

Review 8.  Smoking, p53 mutation, and lung cancer.

Authors:  Don L Gibbons; Lauren A Byers; Jonathan M Kurie
Journal:  Mol Cancer Res       Date:  2014-01       Impact factor: 5.852

9.  Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis.

Authors:  A Bigi; E Beltrami; M Trinei; M Stendardo; P G Pelicci; M Giorgio
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

10.  Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.

Authors:  Don L Gibbons; Wei Lin; Chad J Creighton; Shuling Zheng; Dror Berel; Yanan Yang; Maria Gabriela Raso; Diane D Liu; Ignacio I Wistuba; Guillermina Lozano; Jonathan M Kurie
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.